Preprint / Version 1

In-silico network pharmacology study on Glycyrrhiza glabra: Analyzing the immune-boosting phytochemical properties of Siddha medicinal plant against COVID-19

Authors

  • Karthik Sekaran aSchool of Biosciences and Technology, Vellore Institute of Technology, Vellore, India
  • Ashwini Karthik bDepartment of Biology, Mount Carmel College Autonomous, India
  • Rinku Varghese aSchool of Biosciences and Technology, Vellore Institute of Technology, Vellore, India
  • P Sathyarajeswaran cSiddha Regional Research Institute, Puducherry, India
  • MS Devi dSiddha Central Research Institute, CCRS, Chennai, India
  • R Siva aSchool of Biosciences and Technology, Vellore Institute of Technology, Vellore, India
  • C Doss aSchool of Biosciences and Technology, Vellore Institute of Technology, Vellore, India

Keywords:

Glycyrrhiza glabra, Network pharmacology, Siddha medicine

Abstract

Immunosenescence is a pertinent factor in the mortality rate caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The changes in the immune system are strongly associated with age and provoke the deterioration of the individual’s health. Traditional medical practices in ancient India effectively deal with COVID-19 by boosting natural immunity through medicinal plants. The anti-inflammatory and antiviral properties of Glycyrrhiza glabra are potent in fighting against COVID-19 and promote immunity boost against the severity of the infection. Athimadhura Chooranam, a polyherbal formulation containing Glycyrrhiza glabra as the main ingredient, is recommended as an antiviral Siddha herb by the Ministry of AYUSH. This paper is intended to identify the phytoconstituents of Glycyrrhiza glabra that are actively involved in preventing individuals from COVID-19 transmission. The modulated pathways, enrichment study, and drug-likeness are calculated from the target proteins of the phytoconstituents at the pharmacological activity (Pa) of more than 0.7. Liquiritigenin and Isoliquiritin, the natural compounds in Glycyrrhiza glabra, belong to the flavonoid class and exhibit ameliorative effects against COVID-19. The latter compound displays a higher protein interaction to a maximum of six, out of which HMOX1, PLAU, and PGR are top-hub genes. ADMET screening further confirms the significance of the abovementioned components containing better drug-likeness. The molecular docking and molecular dynamics method identified liquiritigenin as a possible lead molecule capable of inhibiting the activity of the major protease protein of SARS-CoV-2. The findings emphasize the importance of in silico network pharmacological assessments in delivering cost-effective, time-bound clinical drugs. Keywords: Glycyrrhiza glabra, Network pharmacology, Siddha medicine

Downloads